Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diagnostics and biomarker development: priming the pipeline.

Kathryn A Phillips1, Stephanie Van Bebber, Amalia M Issa

  • 1School of Pharmacy, Institute for Health Policy Studies, and University of California San Francisco, 3333 California Street, Room 420, UCSF BOX 0613, San Francisco, California 94143, USA. phillipsk@pharmacy.ucsf.edu

Nature Reviews. Drug Discovery
|May 24, 2006
PubMed
Summary

The medical product pipeline is slowing down, impacting the development of novel biomarkers and diagnostics. This study examines this critical issue and proposes solutions to improve medical innovation delivery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health affairs scholar at year 3: rapid growth, global reach, real-world impact.

Health affairs scholar·2026
Same author

Ten high-priority areas for health policy research in 2026-2027.

Health affairs scholar·2026
Same author

Beyond the "Undruggable": What Pancreatic Cancer Teaches Us About the Next Evolution of Clinical Pharmacology.

Clinical pharmacology in drug development·2026
Same author

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

The Work Behind the First Dose: How Early Clinical Studies Shape the Course of Drug Development.

Clinical pharmacology in drug development·2026
Same author

The potential survival gain and cost-effectiveness of circulating tumor DNA-guided treatment switching in advanced non-small cell lung cancer: A simulation modeling study.

The journal of liquid biopsy·2026

Area of Science:

  • Biomedical research
  • Medical diagnostics
  • Biomarker discovery

Background:

  • Declining rates of novel medical product approvals despite scientific advancements.
  • The 'pipeline problem' is a recognized issue in pharmaceutical development.
  • The specific challenges within biomarker and diagnostic pipelines are underexplored.

Purpose of the Study:

  • To characterize the pipeline problem for biomarkers and diagnostics.
  • To identify unique challenges in biomarker and diagnostic development.
  • To propose solutions for accelerating the delivery of these medical innovations.

Main Methods:

  • Literature review of current challenges in biomarker and diagnostic development.
  • Analysis of regulatory and commercialization pathways.

Related Experiment Videos

  • Expert consultation on potential solutions.

    • Main Results:

    • Identification of key bottlenecks in the biomarker and diagnostic pipeline.
    • Characterization of factors contributing to development delays.
    • Specific examples of successful and unsuccessful product trajectories.

    Conclusions:

    • Addressing the pipeline problem requires a multi-faceted approach.
    • Streamlining regulatory processes and improving funding models are crucial.
    • Enhanced collaboration between researchers, industry, and regulators can accelerate innovation.